Tvardi Therapeutics posts KOL webinar deck on TTI-109 potential in ulcerative colitis

Tvardi Therapeutics posted a medical research presentation outlining the rationale for STAT3 inhibition in ulcerative colitis using its oral STAT3 program.

• Slides position TTI-109 as an oral prodrug of TTI-101, targeting STAT3 nuclear function as a convergent hub across inflammatory pathways.
• The presentation highlights prior clinical observations for TTI-101, including reduced pY-STAT3 target engagement and declines in IL-6 and fibrosis measures.
• Phase 1 multiple-ascending-dose data for TTI-109 showed placebo-adjusted reductions in STAT3-driven immune populations, including Th17, Tfh, and B cells.
• The document also outlines a proposed proof-of-concept trial design for ulcerative colitis.